OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC).

C. Aghajanian, N. J. Finkler, T. Rutherford et al. · Journal of Clinical Oncology · 2011

LBA5007 The full, final text of this abstract will be available in Part II of the 2011 Annual Meeting Proceedings, distributed onsite at the Meeting on June 4, 2011, and as a supplement to the June 20, 2011, issue of Journal of Clinical Oncology.

Cited by 21 works. doi:10.1200/jco.2011.29.15_suppl.lba5007

Authors